Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) EBT: 2009-2025

Historic EBT for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to -$26.2 million.

  • Myriad Genetics' EBT fell 23.58% to -$26.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$425.3 million, marking a year-over-year decrease of 264.75%. This contributed to the annual value of -$123.5 million for FY2024, which is 52.90% up from last year.
  • As of Q3 2025, Myriad Genetics' EBT stood at -$26.2 million, which was up 92.08% from -$330.6 million recorded in Q2 2025.
  • Over the past 5 years, Myriad Genetics' EBT peaked at $39.8 million during Q3 2021, and registered a low of -$330.6 million during Q2 2025.
  • Its 3-year average for EBT is -$70.2 million, with a median of -$37.2 million in 2024.
  • As far as peak fluctuations go, Myriad Genetics' EBT skyrocketed by 191.08% in 2021, and later slumped by 788.71% in 2025.
  • Over the past 5 years, Myriad Genetics' EBT (Quarterly) stood at -$43.5 million in 2021, then fell by 19.77% to -$52.1 million in 2022, then surged by 38.00% to -$32.3 million in 2023, then dropped by 21.05% to -$39.1 million in 2024, then decreased by 23.58% to -$26.2 million in 2025.
  • Its EBT stands at -$26.2 million for Q3 2025, versus -$330.6 million for Q2 2025 and -$29.4 million for Q1 2025.